Summary & Overview
CPT 0233U: Genomic Unity FXN Analysis, PCR-Free Whole Genome Sequencing
CPT code 0233U designates the Genomic Unity® FXN Analysis, a Proprietary Laboratory Analyses (PLA) test that uses PCR-free whole genome sequencing and algorithmic data analysis of blood or saliva to evaluate the frataxin (FXN) gene for variants associated with conditions such as Friedreich’s ataxia. This single-source PLA code matters nationally because it identifies a manufacturer-specific genomic assay that can affect coverage determinations, prior authorization workflows, and claims processing across commercial and public payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose and service setting of the test, payor coverage considerations, common billing modifiers, and where to locate additional coding and manufacturer information. The publication summarizes benchmarks and policy-relevant topics affecting PLA-coded genomic tests, such as how single-source codes influence payer medical policy language and billing granularity. Data not available in the input will be noted as such in relevant sections.
Billing Code Overview
CPT code 0233U is a Proprietary Laboratory Analyses (PLA) code reported for the Genomic Unity® FXN Analysis from Variantyx Inc. The test evaluates the frataxin (FXN) gene for variants relevant to conditions such as Friedreich’s ataxia using a blood or saliva specimen.
Service Type: Genetic testing — PCR-free whole genome sequencing (WGS) with algorithmic analysis
Typical Site of Service: Clinical laboratory (specimens collected from blood or saliva; sequencing and analysis performed in a laboratory setting)
Clinical & Coding Specifications
Clinical Context
A 12-year-old patient presents to a pediatric neurology clinic with progressive gait instability, dysarthria, and a family history suggestive of hereditary ataxia. The neurologist orders a targeted genetic test, 0233U (Genomic Unity® FXN Analysis), using a blood or saliva specimen to evaluate the frataxin (FXN) gene for pathogenic variants associated with Friedreich’s ataxia. The sample is collected in clinic or at a certified collection center and sent to the performing laboratory. The laboratory performs PCR-free whole genome sequencing (WGS) with algorithmic analysis focused on the FXN locus and reports detected variants, zygosity, and interpretation including pathogenicity classification and clinical correlation. Results are returned to the ordering clinician, who integrates molecular findings with clinical exam, family history, and ancillary studies (electrophysiology, cardiac evaluation) to confirm diagnosis, guide genetic counseling, cascade testing of family members, and inform management and surveillance recommendations.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure performed, annotation not required by payer | Rarely used; typically included when no specific modifier applies and payer requires a two-character qualifier. |